Deutsche Bank Analysts Give Celgene (CELG) a $110.00 Price Target

Deutsche Bank set a $110.00 price objective on Celgene (NASDAQ:CELG) in a research report released on Monday morning. The firm currently has a hold rating on the biopharmaceutical company’s stock.

Other equities analysts have also issued research reports about the company. UBS Group lowered Celgene from a strong-buy rating to a market perform rating and set a $160.00 price objective for the company. in a research note on Thursday, October 26th. BMO Capital Markets reduced their price objective on Celgene from $163.00 to $148.00 and set an outperform rating for the company in a research note on Friday, October 27th. Oppenheimer set a $166.00 price objective on Celgene and gave the company a buy rating in a research note on Monday. Jefferies Group reiterated a buy rating and set a $160.00 price objective on shares of Celgene in a research note on Friday, September 15th. Finally, Robert W. Baird lowered Celgene from an outperform rating to a neutral rating and reduced their price objective for the company from $162.00 to $136.00 in a research note on Friday, October 20th. One analyst has rated the stock with a sell rating, fourteen have assigned a hold rating and nineteen have issued a buy rating to the stock. Celgene has an average rating of Buy and a consensus target price of $131.35.

Celgene (CELG) traded up $1.31 during midday trading on Monday, hitting $105.49. The company’s stock had a trading volume of 7,470,000 shares, compared to its average volume of 5,960,000. The stock has a market cap of $83,050.00, a price-to-earnings ratio of 24.88, a P/E/G ratio of 0.68 and a beta of 1.77. Celgene has a twelve month low of $94.55 and a twelve month high of $147.17. The company has a debt-to-equity ratio of 1.31, a current ratio of 3.65 and a quick ratio of 3.52.

Celgene (NASDAQ:CELG) last released its quarterly earnings data on Thursday, October 26th. The biopharmaceutical company reported $1.91 earnings per share for the quarter, beating the Zacks’ consensus estimate of $1.87 by $0.04. The business had revenue of $3.29 billion during the quarter, compared to analyst estimates of $3.42 billion. Celgene had a return on equity of 63.80% and a net margin of 27.36%. The company’s revenue was up 10.2% on a year-over-year basis. During the same quarter last year, the business posted $1.58 EPS. sell-side analysts expect that Celgene will post 6.68 earnings per share for the current year.

A number of large investors have recently bought and sold shares of the business. Capital Investment Services of America Inc. increased its stake in Celgene by 3,368.2% during the 4th quarter. Capital Investment Services of America Inc. now owns 56,531 shares of the biopharmaceutical company’s stock worth $5,900,000 after buying an additional 54,901 shares in the last quarter. New England Research & Management Inc. increased its stake in Celgene by 16.5% during the 4th quarter. New England Research & Management Inc. now owns 12,626 shares of the biopharmaceutical company’s stock worth $1,318,000 after buying an additional 1,792 shares in the last quarter. Abner Herrman & Brock LLC increased its stake in Celgene by 3.3% during the 4th quarter. Abner Herrman & Brock LLC now owns 60,043 shares of the biopharmaceutical company’s stock worth $6,266,000 after buying an additional 1,909 shares in the last quarter. Fulton Bank N.A. increased its stake in Celgene by 2.4% during the 4th quarter. Fulton Bank N.A. now owns 26,128 shares of the biopharmaceutical company’s stock worth $2,727,000 after buying an additional 601 shares in the last quarter. Finally, Renaissance Investment Group LLC increased its stake in Celgene by 21.0% during the 4th quarter. Renaissance Investment Group LLC now owns 46,973 shares of the biopharmaceutical company’s stock worth $4,902,000 after buying an additional 8,143 shares in the last quarter. Institutional investors own 79.74% of the company’s stock.

WARNING: This article was posted by Community Financial News and is the sole property of of Community Financial News. If you are viewing this article on another website, it was copied illegally and reposted in violation of U.S. & international trademark and copyright legislation. The original version of this article can be accessed at https://www.com-unik.info/2018/01/09/deutsche-bank-analysts-give-celgene-celg-a-110-00-price-target.html.

Celgene Company Profile

Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.

Analyst Recommendations for Celgene (NASDAQ:CELG)

Receive News & Ratings for Celgene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit